Monte Rosa Therapeutics (GLUE) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monte Rosa Therapeutics (GLUE) has outperformed Solid Biosciences (SLDB) over the past year, gaining 37.8% versus a gain of 24.1%. Over five years, GLUE leads with a -52.0% price change compared with -79.7% for SLDB. Monte Rosa Therapeutics is the larger company by market cap ($880.4 million vs $731.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLUE | SLDB |
|---|---|---|
| Share price | $10.32 | $6.82 |
| Market cap | $880.43M | $731.28M |
| 1-day change | +1.47% | -0.44% |
| YTD return | -35.14% | +21.45% |
| 1-year return | +37.80% | +24.09% |
| 5-year return | -52.03% | -79.70% |
| EPS (TTM) | $-1.75 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.77 | $11.45 |
| 52-week low | $7.65 | $3.79 |
| Distance from 52-week high | -59.95% | -40.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +171.32% | +173.02% |
| Average volume | 1.31M | 1.09M |
| Shares outstanding | 85.31M | 107.23M |
| Employees | 173 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLUE has outperformed SLDB by 13.7 percentage points over the past year.
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
GLUE vs SLDB FAQ
Which is bigger, Monte Rosa Therapeutics or Solid Biosciences?
Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $880.43M compared with $731.28M for Solid Biosciences (SLDB).
Which stock has performed better over the past year, GLUE or SLDB?
GLUE returned +37.80% over the past 12 months, compared with +24.09% for SLDB (price return, excluding dividends). Past performance does not predict future results.
Are Monte Rosa Therapeutics and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.